Moderna Inc. Chief Financial Officer Jorge Gomez departed a day after taking charge, the vaccine maker said on May 11, following his former employer disclosing an internal probe related to financial reporting.
Halozyme Therapeutics Inc. announced that the company is commencing, through wholly owned subsidiary Atlas Merger Sub Inc., a cash tender offer to purchase all outstanding shares of common stock of Antares Pharma Inc. for $5.60 per share in cash.
Abbott received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation (TRC) to purchase up to 1,000,000 Abbott common shares, representing approximately 0.06% of the company’s outstanding shares.
The U.S. Securities and Exchange Commission (SEC) added 12 China companies to their delisting watchlist.
The U.S. health regulator said on April 5 GlaxoSmithKline and Vir Biotechnology’s antibody therapy was no longer authorized as a COVID-19 treatment, with data suggesting it was unlikely to be effective against the dominant Omicron sub-variant in the country.
Five Chinese companies face potential delisting from Wall Street if they fail to comply with new audit orders from the U.S. Securities and Exchange Commission (SEC).
After months of speculation about looming layoffs, Biogen is handing out pink slips in order to save about $500 million.
According to a filing with the U.S. Security and Exchange Commission, FibroGen is tangled up in a Securities Class Action Litigation as well as Derivative Litigation regarding clinical trial data for the company’s drug Roxadustat, which is being developed with AstraZeneca and Astellas.
Chicago-based AbbVie has been making major decisions with company-wide impacts that could benefit its bottom line.
Shares of Cassava Sciences were up more than 5% in premarket trading on February 11 after the U.S. Food and Drug Administration denied a Citizen Petition filed during 2021 on behalf of short-selling clients who sought to suspend the company’s Alzheimer’s clinical trials.
